Chimeric VSV virus compositions and methods of use thereof for treatment of cancer
Methods of treating cancer including administering to a subject with cancer a pharmaceutical composition including an effective amount of a chimeric VSV virus are disclosed. The chimeric viruses are based on a VSV background where the VSV G protein is replaced with one or more heterologous viral glycoproteins. In the most preferred embodiment, the VSV G protein is replaced with the glycoprotein from Lassa virus or a functional fragment thereof. The resulting chimeric virus is an oncolytic virus that is attenuated and safe in the brain, yet still retains sufficient oncolytic activity to infect and destroy cancer cells such glioblastoma, and to generate an immune response against infected cancer cells. Methods of using chimeric viruses as a platform for immunization against other pathogenic microbes are also provided.
1. A method of treating cancer comprising administering to a subject with cancer a pharmaceutical composition comprising an effective amount of a chimeric Vesicular stomatitis virus (VSV) to treat the cancer,
wherein the chimeric VSV comprises a VSV background with a heterologous viral glycoprotein selected from a Lassa virus glycoprotein and functional fragments thereof, and an Ebola glycoprotein and functional fragments thereof in place of the VSV G-protein.
2. A method of reducing one or more symptoms of cancer in a subject comprising administering to a subject with cancer a pharmaceutical composition comprising an effective amount of a chimeric VSV to reduce one or more symptoms of the cancer in the subject,
wherein the chimeric VSV comprises a VSV background with a heterologous viral glycoprotein selected from a Lassa virus glycoprotein and functional fragments thereof, and an Ebola glycoprotein and functional fragments thereof in place of the VSV G-protein.
3. The method of claim 1 wherein the chimeric VSV genome encodes a Lassa virus glycoprotein precursor (GPC), or a functional fragment thereof.
4. The method of claim 3 wherein the heterologous viral glycoprotein is Lassa virus GP1, Lassa virus GP2, or a combination thereof.
5. The method of claim 1 wherein the VSV background is VSV Indiana, VSV New Jersey, VSV Alagoas, (formerly Indiana 3), VSV Cocal (formerly Indiana 2), VSV Chandipura, VSV Isfahan, VSV San Juan, VSV Orsay, VSV Glasgow, or a recombinant VSV comprising at least 1 gene from two or more VSV strains or serotypes selected from the group consisting of VSV Indiana, VSV New Jersey, VSV Alagoas, (formerly Indiana 3), VSV Cocal (formerly Indiana 2), VSV Chandipura, VSV Isfahan, VSV San Juan, VSV Orsay, and VSV Glasgow.
6. The method of claim 1 wherein the heterologous glycoprotein is from Lassa virus strain Josiah.
7. The method of claim 1 wherein the chimeric VSV further comprises one or more additional heterologous proteins.
8. The method of claim 7 wherein the genome of the chimeric VSV encodes the one or more heterologous genes.
9. The method of claim 7 wherein the one or more additional heterologous proteins is a therapeutic protein, a reporter, a vaccine antigen, a targeting moiety, or a combination thereof.
10. The method of claim 9 wherein the one or more additional heterologous proteins includes at least one therapeutic protein selected from the group consisting of IL-28, IL-2, FLT3L, GM-CSF, IL-4,IL-7, IL-12, and TRAIL.
11. The method of claim 9 wherein the one or more additional heterologous proteins includes at least one reporter selected from the group consisting of green florescent protein, red florescent protein, carcinoembryonic antigen, secreted alkaline phosphatase, and the beta subunit of chorionic gonadotropin.
12. The method of claim 1 wherein the cancer is selected from the group consisting of multiple myeloma, bone, bladder, brain, breast, cervical, colo-rectal, esophageal, kidney, liver, lung, nasopharangeal, pancreatic, prostate, skin, stomach, and uterine.
13. The method of claim 12 wherein the brain cancer is selected from the group consisting of oligodendroglioma, meningioma, supratentorial ependymona, pineal region tumors, medulloblastoma, cerebellar astrocytoma, infratentorial ependymona, brainstem glioma, schwannomas, pituitary tumors, craniopharyngioma, optic glioma, and astrocytoma.
14. The method of claim 12 wherein the brain cancer is glioblastoma.
15. The method of claim 1 wherein the virus is in a dosage of between 10 2 and 10 12 PFU.
16. The method of claim 1 wherein the pharmaceutical composition is administered locally to the site of the cancer.
17. The method of claim 16 wherein the pharmaceutical composition is injected into or adjacent to a tumor in the subject.
18. The method of claim 1 wherein the pharmaceutical composition is administered systemically to the subject.
19. The method of claim 18 wherein the pharmaceutical composition is administered by intravenous injection or infusion.
20. The method of claim 1 wherein the pharmaceutical composition is administered to the subject intranasally or by pulmonary delivery.
21. The method of claim 1 further comprising administering to the subject a second therapeutic agent.
22. The method of claim 21 wherein the second therapeutic agent is an anticancer agent, a therapeutic protein, or an immunosuppressant.
23. The method of claim 22 wherein immunosuppressant is a histone deacetylase (HDAC) inhibitor or an interferon blocker.
24. The method of claim 23 wherein the second therapeutic agent is selected from the group consisting of valproate, the vacccinia protein B 18R, Jak inhibitor 1, and vorinostat.
25. The method of claim 1 wherein the pharmaceutical composition is administered in combination with surgery.
26. The method of claim 25 wherein the surgery is prior to administration of the pharmaceutical composition.
27. The method of claim 1 further comprising administering the subject an immunizing composition comprising a virus effective to immunize to the subject to the chimeric VSV prior to administration of the pharmaceutical composition.
28. The method of claim 27 wherein the virus of the immunizing composition is the chimeric VSV.
29. The method of claim 27 wherein the immunizing composition is administered to the subject days, weeks, or months before administration of the pharmaceutical composition.
30. The method of claim 1 wherein the chimeric VSV shows little or no ability to infect normal or health neurons.
31. The method of claim 1 wherein the chimeric virus is a replication-competent virus.
32. The method of claim 31 wherein the heterologous viral glycoprotein is formed from Lassa virus glycoprotein precursor (GPC).
33. The method of claim 31 wherein the heterologous viral glycoprotein is Ebola glycoprotein.
34. A method of treating cancer comprising administering to a subject with cancer a pharmaceutical composition comprising an effective amount of a chimeric Vesicular stomatitis virus (VSV) to treat the cancer, the chimeric VSV comprising a VSV background with a glycoprotein formed from a Lassa virus glycoprotein precursor (GPC), or a functional fragment thereof in place of the VSV G-protein.
35. The method of claim 34 , wherein the chimeric virus is a replication-competent virus.
36. A method of treating cancer comprising administering to a subject with cancer a pharmaceutical composition comprising an effective amount of a chimeric Vesicular stomatitis virus (VSV) to treat the cancer, the chimeric VSV comprising a VSV background with an Ebola virus glycoprotein, or a functional fragment or variant thereof in place of the VSV G-protein.
37. The method of claim 36 , wherein the chimeric virus is a replication-competent virus.
38. The method of claim 1 , wherein the heterologous glycoprotein is a Lassa virus glycoprotein.
39. The method of claim 1 , wherein the heterologous glycoprotein is an Ebola virus glycoprotein.
40. The method of claim 2 , wherein the heterologous glycoprotein is a Lassa virus glycoprotein.
41. The method of claim 2 , wherein the heterologous glycoprotein is an Ebola virus glycoprotein.
42. The method of claim 1 , the chimeric virus has a higher oncolytic potential than the parent virus of the chimeric VSV wherein the G protein is not replaced with a heterologous glycoprotein.
43. The method of claim 2 , the chimeric virus has a higher oncolytic potential than the parent virus of the chimeric VSV wherein the G protein is not replaced with a heterologous glycoprotein.
44. The method of claim 2 wherein the chimeric VSV further comprises one or more additional heterologous proteins.
45. The method of claim 2 wherein the one or more additional heterologous proteins is a therapeutic protein, a reporter, a vaccine antigen, a targeting moiety, or a combination thereof.
46. The method of claim 2 wherein the cancer is selected from the group consisting of multiple myeloma, bone, bladder, brain, breast, cervical, colo-rectal, esophageal, kidney, liver, lung, nasopharangeal, pancreatic, prostate, skin, stomach, and uterine.
47. The method of claim 46 wherein the brain cancer is selected from the group consisting of glioblastoma, oligodendroglioma, meningioma, supratentorial ependymona, pineal region tumors, medulloblastoma, cerebellar astrocytoma, infratentorial ependymona, brainstem glioma, schwannomas, pituitary tumors, craniopharyngioma, optic glioma, and astrocytoma.